Inventor profile of:

Marc Mansour

City:

Halifax

Country:

Canada

Published Applications:

24

Last publication date:

2023-05-04

Top Assignees for applications by Marc Mansour

The entities that hold a legal rights for patent applications filed by inventor Mansour Marc:

Recent patent applications by Mansour Marc

Marc Mansour from Halifax, CA has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2023-05-04
US20230137174A1
Human necessities

NOVEL SALMONELLA-BASED CORONAVIRUS VACCINE

#2 | 2022-11-03
US20220347296A1
Human necessities

Methods of using low dose volume B-cell epitope compositions for inducing an antibody immune response in human subjects

#3 | 2022-01-06
US20220001010A1
Human necessities

ADJUVANTING SYSTEMS AND WATER-FREE VACCINE COMPOSITIONS COMPRISING A POLYI:C POLYNUCLEOTIDE ADJUVANT AND A LIPID-BASED ADJUVANT

#4 | 2021-10-21
US20210322573A1
Human necessities

USE OF LIPOSOMES IN A CARRIER COMPRISING A CONTINUOUS HYDROPHOBIC PHASE FOR DELIVERY OF POLYNUCLEOTIDES IN VIVO

#5 | 2021-10-07
US20210308252A1
Human necessities

LIPOSOME COMPOSITIONS COMPRISING PAM2CYS OR PAM3CYS ADJUVANT AND METHODS FOR INDUCING A HUMORAL IMMUNE RESPONSE

#6 | 2021-02-25
US20210052724A1
Human necessities

METHOD FOR IMPROVING THE EFFICACY OF A SURVIVIN VACCINE IN THE TREATMENT OF CANCER

#7 | 2020-04-09
US20200109160A1
Chemistry; metallurgy

Lipid A mimics, methods of preparation, and uses thereof

#8 | 2019-09-26
US20190290743A1
Human necessities

Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance

#9 | 2019-07-25
US20190224338A1
Human necessities

Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo

#10 | 2019-07-25
US20190224312A1
Human necessities

Methods of using low dose volume B-cell epitope compositions for inducing an antibody immune response in human subjects

#11 | 2019-05-16
US20190142928A1
Human necessities

Liposome compositions comprising PAM2Cys or PAM3Cys adjuvant and methods for inducing a humoral immune response

#12 | 2018-11-29
US20180339039A1
Human necessities

Adjuvanting systems and water-free vaccine compositions comprising a polyI:C polynucleotide adjuvant and a lipid-based adjuvant

#13 | 2018-10-11
US20180289801A1
Human necessities

Method for improving the efficacy of a survivin vaccine in the treatment of cancer

#14 | 2018-06-28
US20180177726A1
Human necessities

Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment

#15 | 2018-01-11
US20180009833A1
Chemistry; metallurgy

Lipid A mimics, methods of preparation, and uses thereof

#16 | 2017-02-02
US20170028084A1
Human necessities

Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo

#17 | 2016-03-10
US20160067335A1
Human necessities

Method for improving the efficacy of a survivin vaccine in the treatment of cancer

#18 | 2015-07-23
US20150202152A1
Human necessities

Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment

#19 | 2014-08-21
US20140234404A1
Human necessities

Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof

#20 | 2011-03-24
US20110070298A1
Human necessities

Compositions Comprising Liposomes, An Antigen, A Polynucleotide and A Carrier Comprising a Continuous Phase of a Hydrophobic Substance

#21 | 2010-08-19
US20100209452A1
Human necessities

COMPOSITIONS COMPRISING AN ANTIGEN, AN AMPHIPATHIC COMPOUND AND A HYDROPHOBIC CARRIER, AND USES THEREOF

#22 | 2010-08-12
US20100203116A1
Human necessities

Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo

#23 | 2009-12-03
US20090297593A1
Human necessities

Use of Liposomes in a Carrier Comprising a Continuous Hydrophobic Phase as a Vehicle for Cancer Treatment

#24 | 2006-06-06
US10636620
-

Antigens for immunocontraception

InventorID:

879292 ⎘